Valletta, Malta | 27 April 2026
Pancreatic Cancer Europe (PCE) marked its 10th Anniversary with the delivery of an exclusive, invitation-only masterclass titled “Pancreatic Cancer: a comprehensive overview on latest developments”, held in Valletta, Malta, with the support of the Ministry for Health and Active Ageing (Malta).
The masterclass brought together a select group of leading experts, clinicians, and healthcare professionals from across Europe, creating a focused environment for high-level exchange on the most pressing challenges in pancreatic cancer care.
Advancing knowledge and collaboration
The programme addressed key priorities across the pancreatic cancer pathway, including early diagnosis, prevention, treatment optimisation, and patient-centred care. Discussions emphasised the urgent need to improve outcomes through earlier detection, multidisciplinary collaboration, and the integration of research into clinical practice.
Distinguished speakers
The session featured contributions from internationally recognised experts:
- Dr Clarence Pace (Malta) – Government Medical Officer
- Hon. Jo Etienne Abela (Malta) – Minister for Health and Active Ageing
- Ilse Rooman (Belgium) – PCE Board Member and Vice Chair
- Nuria Malats (Spain) – CNIO
- Eithne Costello (United Kingdom) – University of Liverpool
- Matthias Löhr (Sweden) – Karolinska Institute
- Rebecca Dalli (Malta) – Mater Dei Hospital
- Salvatore Paiella (Italy) – University of Verona
- Alfredo Carrato (Spain) – European Pancreatic Club / Hospital Ramón y Cajal
A decade of impact
Celebrating ten years since its establishment, PCE continues to play a pivotal role in uniting stakeholders across Europe to improve pancreatic cancer outcomes. This anniversary masterclass reflects PCE’s ongoing commitment to advancing policy, research, and clinical practice through collaboration and knowledge sharing.
Looking ahead
The discussions in Valletta reinforced the importance of sustained, coordinated action at both national and European levels. PCE remains dedicated to driving progress and ensuring that patients affected by pancreatic cancer benefit from timely diagnosis, equitable access to care, and innovative treatment approaches.